Evidence map›Paper›PMID 35490916›Full record

ArticleAnaerobe2022

Methotrexate promotes recovery of arthritis-induced alveolar bone loss and modifies the composition of the oral-gut microbiota.

José Alcides Almeida de Arruda, Jôice Dias Corrêa, Youvika Singh, Sicília Rezende Oliveira, Caio Cavalcante Machado, Ayda Henriques Schneider, Julliane Dutra Medeiros, Gabriel R Fernandes, Soraia Macari, Breno Rocha Barrioni and 7 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Anaerobe, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 2 countries.

José Alcides Almeida de ArrudaDepartment of Oral Surgery, Pathology and Clinical Dentistry, School of Dentistry, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
Jôice Dias CorrêaDepartment of Dentistry, Pontifical Catholic University, Belo Horizonte, MG, Brazil.
Youvika SinghDepartment of Clinical and Toxicological Analysis, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP, Brazil.
Sicília Rezende OliveiraDepartment of Oral Surgery, Pathology and Clinical Dentistry, School of Dentistry, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
Caio Cavalcante MachadoDepartment of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
Ayda Henriques SchneiderDepartment of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
Julliane Dutra MedeirosFaculty of Biological and Agricultural Sciences, Mato Grosso State University, Alta Floresta, MT, Brazil.
Gabriel R FernandesOswaldo Cruz Fundation, René Rachou Research Center, Belo Horizonte, MG, Brazil.
Soraia MacariDepartment of Restorative Dentistry, School of Dentistry, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
Breno Rocha BarrioniDepartment of Metallurgical and Materials Engineering, Faculty of Engineering, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
Mariana de Souza SantosDepartment of Restorative Dentistry, School of Dentistry, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
Letícia Fernanda DufflesDepartment of BioMolecular Sciences, School of Pharmacological Science, University of São Paulo, Ribeirão Preto, SP, Brazil.
Helder Takashi Imoto NakayaDepartment of Clinical and Toxicological Analysis, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP, Brazil.
Sandra Yasuyo FukadaDepartment of BioMolecular Sciences, School of Pharmacological Science, University of São Paulo, Ribeirão Preto, SP, Brazil.
Dana T GravesDepartment of Periodontics, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Fernando Queiroz CunhaDepartment of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil. Electronic address: fdqcunha@fmrp.usp.br.
Tarcília Aparecida SilvaDepartment of Oral Surgery, Pathology and Clinical Dentistry, School of Dentistry, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. Electronic address: silva.tarcilia@gmail.com.
Universidade de São Paulo · BRUniversidade Federal de Minas Gerais · BRFundação Oswaldo Cruz · BRPontifícia Universidade Católica de Minas Gerais · BRUniversidade de Ribeirão Preto · BRUniversidade do Estado de Mato Grosso · BRUniversity of Pennsylvania · US

Funding

Diabetes-enhanced Experimental PeriodontitisR01DE017732 · NIDCR · UNIV OF MED/DENT OF NJ-NJ DENTAL SCHOOL · PI DANA T GRAVES · 2007 to 2026
$6.5M
Dendritic Cells and Periodontal DiseaseR01DE021921 · NIDCR · UNIVERSITY OF PENNSYLVANIA · PI GRAVES, DANA T · 2012 to 2022
$4.2M
NIDCR NIH HHS R01 DE017732NIDCR NIH HHS R01 DE021921
6 · The paper itself

Abstract

objectivesThe impact of rheumatoid arthritis (RA) on the shaping of the oral and gut microbiome raises the question of whether and how RA treatment modifies microbial communities. We examined changes in the oral and gut microbiota in a mouse model of antigen-induced arthritis (AIA) treated or not with methotrexate (MTX).

methodsMaxillae and stools were evaluated by the MiSeq platform of the V4 region of the 16S rRNA gene. Alveolar bone parameters were analysed by micro-computed tomography. Moreover, arthritis-induced changes in hyperalgesia and oedema were assessed, along with the impact on periodontal bone health.

resultsMicrobial communities in MTX-treated AIA mice revealed distinct clusters compared to the control and AIA groups. Overall, MTX impacted the richness and variability of microorganisms in the oral-gut axis microbiome at the phylum level. Regarding the oral microbiome, while in the control group the most dominant phylum was Firmicutes, in the AIA group there was a shift towards the predominance of Campilobacteriota and Bacteroidetes associated with the disease. MTX treatment led to greater dominance of the health-associated phylum Proteobacteria. In the gut microbiome, AIA induction resulted in increased abundance of the Verrucomicrobiota phylum, and MTX treatment restored its levels compared to control. Importantly, the MTX-treated AIA animals had significantly less periodontal bone loss, as well as decreased hyperalgesia and joint oedema compared to the AIA animals.

conclusionData suggest the benefit of MTX treatment in protecting alveolar bone, in addition to providing new insights on the drug-microbiome interaction in the course of RA.

Indexed as

Alveolar Bone LossArthritis, ExperimentalArthritis, RheumatoidGastrointestinal MicrobiomeMicrobiotaAnimalsEdemaHyperalgesiaMethotrexateMiceRNA, Ribosomal, 16SX-Ray MicrotomographyMethotrexateRNA, Ribosomal, 16SAlveolar bone lossAntirheumatic agentsGut microbiomeMethotrexateMicrobiotaRheumatoid arthritis

Identifiers

PMID35490916
PMCPMC10782845
OpenAlexW4224995895

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.